Search
GS-9191
go.drugbank.com/drugs/DB15084InvestigationalGS-9191 is under investigation in clinical trial NCT00499967 (Safety and Effectiveness Study of an Experimental Topical Ointment (GS-9191) for the Treatment of Genital Warts).
Categories: P-glycoprotein inhibitorsGlutamine 2-n-15
go.drugbank.com/drugs/DB15103ExperimentalGlutamine 2-n-15 is under investigation in clinical trial NCT01912235 (Arginine Synthesis in Healthy Adult Humans).
Synonyms: Glutamine 2-n-15, L-GLUTAMINE-N2-15NInterferon alfa-2c
go.drugbank.com/drugs/DB15131InvestigationalInterferon alfa-2c is under investigation in clinical trial NCT00485563 (A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma).
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme InhibitorsElexacaftor
go.drugbank.com/drugs/DB15444ApprovedInvestigationalElexacaftor (previously VX-445) is a small molecule, next-generation corrector of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. It received FDA approval in October 2019 in combination with tezacaftor and ivacaft...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesPradefovir
go.drugbank.com/drugs/DB15550InvestigationalPradefovir is a prodrug of adefovir.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesDesfesoterodine
go.drugbank.com/drugs/DB15578InvestigationalDesfesoterodine is a metabolite of tolterodine.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesCryptotanshinone
go.drugbank.com/drugs/DB15579ExperimentalCategories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2C9 InhibitorsJPC-3210
go.drugbank.com/drugs/DB15609ExperimentalJPC-3210 is a potent antimalarial agent. It is an erythrocytic schizonticide with potent in vitro antimalarial activity against multidrug-resistant Plasmodium falciparum lines, low cytotoxicity, potent in vivo efficacy against murine mal...
Categories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP3A InhibitorsPralsetinib
go.drugbank.com/drugs/DB15822ApprovedInvestigationalPralsetinib, similar to the previously approved selpercatinib, is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes. Enhanced RET (Rearranged during transfection) oncogene expres...
Categories: P-glycoprotein inhibitors, P-glycoprotein substrates